ZCCHC17:在阿尔茨海默氏病中是突触功能障碍和神经元刺激性的目标
Brittany A Klub1, Andrew F Teich2,3,4, Giuseppe P Cortese1,5
1Touro College of Osteopathic Medicine, Touro University, Great Falls, MT, United States.
Frontiers in aging neuroscience
|February 26, 2026
概括
阿尔茨海默氏病 (AD) 涉及由于减少ZCCHC17蛋白质而导致神经元过度兴奋,影响突触功能. 恢复ZCCHC17可能为早期AD干预提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 与活动和神经元刺激能力的改变有关.
- 向激发主导的转变是AD中大脑过度活跃的基础,影响神经传递.
- 突触功能障碍是AD病变发生的一个关键特征.
研究的目的:
- 审查指CCHC类型含有17 (ZCCHC17) 在阿尔茨海默氏症 (AD) 大脑中的作用.
- 探索ZCCHC17是如何调节AD中神经元过敏性机制的.
- 突出ZCCHC17作为AD中突触功能障碍的潜在调节者.
主要方法:
- 文献综述侧重于AD中ZCCHC17的表达和功能.
- 分析ZCCHC17在RNA处理和突触调节中的作用.
- 检查ZCCHC17与神经元过度兴奋性和AD进展的联系.
主要成果:
- 在AD大脑中,ZCCHC17的表达在结晶体和神经元损失之前显著降低.
- 降低ZCCHC17水平与异常RNA处理和神经元过敏性有关.
- ZCCHC17被认为是AD中突触功能障碍的主调节者.
结论:
- 在AD中,ZCCHC17在调节突触功能和神经元刺激性方面发挥着关键作用.
- 了解ZCCHC17的功能可能会导致AD的早期诊断和治疗方法得到改善.
- 准ZCCHC17可能会提供一种新的方法来挽救预发性AD中的突触功能障碍.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
735
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
735
Role of Neurotransmitters in Memory
2.7K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.7K


